Form 4 for AQST Aquestive Therapeutics, Inc.
Accepted 2026-06-24 11:11:33 ET · period of report 2026-06-23 · accession 0001214659-26-007677 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-24 11:11 | 2026-06-23 | AQST | Krop Julie | Dir | M - OptEx | $0.7132 | +25.0K | 25.0K | New | +$17.8K |
| DT | 2026-06-24 11:11 | 2026-06-23 | AQST | Krop Julie | Dir | S - Sale+OE | $5.02 | -25.0K | 0 | -100% | -$125.4K |
| DT | 2026-06-24 11:11 | 2026-06-23 | AQST | Krop Julie | Dir | M - OptEx | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-23 | M | A | 25,000 | $0.7132 | 25,000 | D | — | — | (F1) This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. |
| 2 | Common | Common Stock | 2026-06-23 | S | D | 25,000 | $5.02 | 0 | D | — | — | (F2) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-23 | M | D | 25,000 | $0.00 | 0 | D | $0.7132 · — to 2032-06-22 | 25,000 Common Stock | (F1) This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. (F3) This option was granted on June 22, 2022 and is fully vested. |